Tuesday, September 1, 2026 See who Washington just made rich Get the free brief →
Money Racket
Who Cashes In When Washington Moves
DEFENSEBoeing Wins $131B F-15 Contract—Fighter Jet DominanceyesterdayHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win4 weeks agoCRYPTOSEC Proposes Crypto Offering Exemptions—Regulatory ClarityyesterdayDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenue4 weeks agoENERGYCentrus HALEU Enrichment Wins Policy Tailwind—Nuclear FuelyesterdayWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Market4 weeks agoHEALTHCARE & FDAWhat Is a PDUFA Date?yesterdayHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruption4 weeks agoMARKETSWhat Is a Negotiated PriceyesterdayENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risk4 weeks agoHEALTHCARE & FDAFDA Approves Mimrylo for Polycythemia Vera3 days agoTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeeze4 weeks agoHEALTHCARE & FDAFDA Authorizes Generic Bimectin for Screwworm Prevention3 days agoHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Win4 weeks agoHEALTHCARE & FDAFDA Opens GenAI Medical Device Regulation to Public Input3 days agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressure4 weeks agoHEALTHCARE & FDATrump Admin Blocks $1.6B in Fraudulent Medicare Lab Payments3 days agoHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relief4 weeks agoTECHNHTSA Extends Comment Period on Vehicle Safety Exemptions3 days agoTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestone4 weeks agoENERGYBLM Launches 30-Year Permit for Trans-Alaska Pipeline Operations4 days agoDEFENSERising Defense Spending Lifts Northrop Grumman Outlook4 weeks agoMARKETSFTC Blocks Henkel's $725M Liquid Nails Bid—Antitrust Wins4 days agoMARKETSFTC Threatens Booking Holdings Over Priceline Practices4 weeks agoHEALTHCARE & FDAFDA Approves First RAS Inhibitor for Pancreatic Cancer5 days agoHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practices4 weeks agoDEFENSEBoeing Lands $131B F-15 Contract—Fighter Jet Dominance5 days agoHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanoma4 weeks agoHEALTHCARE & FDACostco Enters Medicare Advantage—Retail Disruption Looms5 days agoTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payout3 weeks agoTRADE & TARIFFSTrump's 50% Canada Tariffs Take Effect—Retailers Brace5 days agoTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backing3 weeks agoTRADE & TARIFFSU.S. Rolls Out Iran Sanctions—Oil Prices Slip5 days agoWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employers3 weeks agoHEALTHCARE & FDAAbbott's Dual Glucose-Ketone Monitor Wins FDA Nod6 days agoENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakes3 weeks agoHEALTHCARE & FDARegeneron's Gene Therapy Wins First GSD Type Ia Approval6 days agoDEFENSEPentagon Awards Space-Based Target Tracking Contracts3 weeks agoDEFENSEStryker Lands $100M Defense Contract—Combat Vehicle Boost6 days agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfolio3 weeks agoTRADE & TARIFFSWalmart Deploys $2.9B Tariff Refund Into Price Cuts6 days agoWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty3 weeks agoTRADE & TARIFFSTrump Lifts Ground Beef Tariffs—Ranchers Face Price Pressure6 days agoDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains3 weeks agoWHITE HOUSETrump Kills Affirmative Action Rules—Contractors Face Compliance Shiftlast weekWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift3 weeks agoHEALTHCARE & FDAFDA Clears Robotic Blood Draw—Phlebotomy Shortage Easeslast weekWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing3 weeks agoWHITE HOUSELabor Dept Eases Disability Hiring Rules—Contractors Save Compliance Costslast weekHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance3 weeks agoWHITE HOUSELabor Dept Eases Veteran Hiring Rules—Contractors Cut Compliancelast weekENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask3 weeks agoTECHCHIPS Act Transforms Binghamton Into Semiconductor Hublast weekHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock3 weeks agoTRADE & TARIFFSTrump Administration Targets Iran's Banking System With New Sanctionslast weekDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract3 weeks agoTECHUtah Governor Signs Quantum Computing Initiative Orderlast weekTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility3 weeks agoDEFENSEFAA Engine Inspection Order Lifts MRO Stockslast weekDEFENSEBlackSky Lands Multi-Year Satellite Contract3 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earningslast weekHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Wins3 weeks agoHEALTHCARE & FDATrump Vaccine Spacing Order Reshapes Pharma Demandlast weekTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makers2 weeks agoTECHD-Wave Wins Canadian Quantum Funding for Annealinglast weekTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refund2 weeks agoENERGYEnbridge Wins Federal Permit for Line 5 Tunnellast weekCRYPTOSEC Delays Crypto Rules—Uncertainty Persists2 weeks agoENERGYFederal Court Orders Enbridge Line 5 Removallast weekTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings2 weeks agoWHITE HOUSEFinCEN Finalizes BOI Exemption for U.S. Personslast weekENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks Path2 weeks agoHEALTHCARE & FDAGAO Finds $7.6B Medicare Hospice Overpaymentlast weekTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings Boost2 weeks agoENERGYNewsom Passes Diablo Canyon Decision to Successorlast weekHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face Pressure2 weeks agoDEFENSERTX Lands Fresh Missile Defense Contract—Stock Undervaluedlast weekWHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma Demand2 weeks agoTECHCommerce Eases Drone Export Rules—U.S. Makers Winlast weekENERGYEPA Exempts Calcium Carbonate From Pesticide Tolerance—Farm Input Eases2 weeks agoHEALTHCARE & FDAFDA Reclassifies Cancer Tests—Easier Path for Diagnostics2 weeks agoDEFENSETrump's $1.5T Defense Push Fuels Colorado Contractor Windfall2 weeks agoHEALTHCARE & FDAFTC Probes Epic Systems Over Health Records Monopoly2 weeks ago
Healthcare & FDA

What Is a PDUFA Date?

The FDA deadline that can move biotech stocks 20% in a single day.

Image: Money Racket
By at Money Racket · Aug 31, 2026

A PDUFA date is the deadline by which the FDA must make a decision on a drug approval application. PDUFA stands for Prescription Drug User Fee Act, a 1992 law that lets the FDA collect fees from drug makers to fund faster reviews. The date is set when the FDA accepts an application for review and is typically 10 months out for standard review or 6 months for priority review.

A small-cap biotech with one drug in the pipeline might move 30-50% on PDUFA day.

The PDUFA date is not a guarantee of approval—it's a decision deadline. The FDA can approve, reject, or request more data by that date. For investors, it matters enormously because biotech companies often have their entire valuation riding on a single drug candidate, and the PDUFA date is when the market finds out if that bet pays off.

How it works in practice

When a biotech company submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA, the agency assigns a PDUFA date within days. That date becomes a hard stop on the FDA's review clock. The company knows exactly when a yes-or-no answer is coming. Investors mark their calendars.

On PDUFA date, the FDA issues a decision letter. An "approval" letter means the drug can be sold. A "complete response letter" (CRL) means the FDA wants more data, more trials, or manufacturing changes—back to the drawing board, sometimes for another 12+ months. A "refuse to file" is rare but means the application was incomplete from the start.

Why this matters to stock prices

A PDUFA date is a binary event. There's no middle ground. The stock either gets good news or bad news on a specific day. Biotech stocks often trade on hope and hype leading up to the date, then crater or spike on the actual decision. A small-cap biotech with one drug in the pipeline might move 30-50% on PDUFA day.

Large pharma companies with diversified pipelines feel PDUFA dates less acutely, but a blockbuster drug approval can still move the needle. Investors who own biotech ahead of a PDUFA date are betting on approval; those who short it are betting on rejection or delay.

The calendar as a trading tool

Serious biotech investors track PDUFA dates the way sports bettors track game schedules. Websites like BiopharmGuy and the FDA's own CDER database list upcoming PDUFA dates by month. Knowing which companies have catalysts coming—and when—lets you size positions and manage risk around known volatility events.

The PDUFA date is also a forcing function for management. If a company's lead drug gets a CRL instead of approval, the stock often drops 40-60% in a day. That's why biotech CEOs spend months before PDUFA dates preparing for both outcomes and sometimes pre-announcing data to soften the blow if results are weak.

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Knowing who cashed in is only half the trade.

Every catalyst has a second move — the supplier, the sector, the part already priced in. Money Racket Pro hands you that read on every policy event, plus the pre-market brief six mornings a week, before the open.

Get the edge · $40/mo

Join the readers who get there before the financial press. Cancel anytime, one click.

Share

https://moneyracket.com/article/gsc-pdufa-date/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Get the free brief The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Get the free brief →